| |
Pricing of Drugs and Formulary Placement: Making Sense of Hepatitis C Treatment
Camilla S. Graham, MD, MPH
|
| |
| |
Download the PDF here
Co-Director, Viral Hepatitis Center, Division of Infectious Disease
Beth Israel Deaconess Medical Center and Harvard Medical School
Boston, Massachusetts
Tuesday, March 31, 2015
GOLD SUPPORTERS
Bristol-Myers Squibb
AbbVie
Gilead Sciences, Inc
SILVER SUPPORTER
Merck & Co, Inc
https://www.iasusa.org/content/pricing-of-drugs-and-formulary-placement-webinar-2015
https://iasusa.adobeconnect.com/_a1090822362/p2h0yk85lmq/?launcher=false&fcsContent=true&pbMode=normal
(ok to skip the first 5-7 minutes of the presentation)
Confusion and doubt: Who should we be treating?
Fear of testing: Why make people anxious and not be able to treat them?
Public health programs stymied because why find people and then not be able to treat them?
Deliberate rationing
Vulnerable patient population already stigmatized, now experiencing overt discrimination, in effect telling patients they aren't worthy of being treated.
Landscape is complex and changing quickly.
How did we get ourselves into this mess?
|
|
| |
| |
|
|
|
